Journey Medical in-licenses, launches Accutane

Journey Medical, a partner company of Fortress, announced that it has in-licensed and launched an oral isotretinoin under the brand name Accutane (isotretinoin capsules).

Accutane is an oral medication that is indicated for the treatment of severe recalcitrant nodular acne.

“We are proud to add Accutane to our growing portfolio of dermatology products, which also includes Targadox (doxycycline hyclate tablets) and Ximino (minocycline hydrochloride extended-release capsules)," said Claude Maraoui, president and CEO of Journey Medical. "Licensing and launching Accutane allows us to leverage the strength of its brand name with our experienced acne sales team. We are poised for an exciting year as we launch this brand under the Journey Medical umbrella.”

Lindsay Rosenwald, chairman, president and CEO of Fortress, added, “The in-licensing of Accutane and expansion of Journey Medical’s portfolio of branded dermatology products showcases Fortress’ unique business model designed to acquire and rapidly advance overlooked yet potentially transformative assets to patients. We are excited about the growth potential that this newly acquired product will bring to our revenue-generating partner company.”